Bischof M - Search Results

1

Approaches for economic evaluations of health care technologies.

Tarride JE, Blackhouse G, Bischof M, McCarron EC, Lim M, Ferrusi IL, Xie F, Goeree R. Tarride JE, et al. Among authors: bischof m. J Am Coll Radiol. 2009 May;6(5):307-16. doi: 10.1016/j.jacr.2009.01.011. J Am Coll Radiol. 2009. PMID: 19394571

2

Health technology assessment and primary data collection for reducing uncertainty in decision making.

Goeree R, Levin L, Chandra K, Bowen JM, Blackhouse G, Tarride JE, Burke N, Bischof M, Xie F, O'Reilly D. Goeree R, et al. Among authors: bischof m. J Am Coll Radiol. 2009 May;6(5):332-42. doi: 10.1016/j.jacr.2009.01.012. J Am Coll Radiol. 2009. PMID: 19394574

3

A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment.

Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R. Tarride JE, et al. Among authors: bischof m. Pharmacoeconomics. 2010;28(4):255-77. doi: 10.2165/11531590-000000000-00000. Pharmacoeconomics. 2010. PMID: 20222752 Review.

4

A review of health utilities across conditions common in paediatric and adult populations.

Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K, Xie F, O'Reilly D, Goeree R. Tarride JE, et al. Among authors: bischof m. Health Qual Life Outcomes. 2010 Jan 27;8:12. doi: 10.1186/1477-7525-8-12. Health Qual Life Outcomes. 2010. PMID: 20105304 Free PMC article. Review.

5

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands.

Velikanova R, van der Schans S, Bischof M, van Olden RW, Postma M, Boersma C. Velikanova R, et al. Among authors: bischof m. Value Health. 2022 Oct;25(10):1696-1704. doi: 10.1016/j.jval.2022.06.010. Epub 2022 Aug 11. Value Health. 2022. PMID: 35963838 Free article.

6

Cost-effectiveness of extended venous thromboembolism prophylaxis with fondaparinux in hip surgery patients.

Bischof M, Leuppi JD, Sendi P. Bischof M, et al. Expert Rev Pharmacoecon Outcomes Res. 2006 Apr;6(2):171-80. doi: 10.1586/14737167.6.2.171. Expert Rev Pharmacoecon Outcomes Res. 2006. PMID: 20528553

7

Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.

Bischof M, Briel M, Bucher HC, Nordmann A. Bischof M, et al. Value Health. 2009 Jul-Aug;12(5):649-56. doi: 10.1111/j.1524-4733.2009.00513.x. Value Health. 2009. PMID: 19490551 Free article.

8

Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.

Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H. Petrou S, et al. Among authors: bischof m. Pediatrics. 2006 May;117(5):1640-9. doi: 10.1542/peds.2005-1150. Pediatrics. 2006. PMID: 16651318 Clinical Trial.

9

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.

Zimovetz EA, Beard SM, Hodgkins P, Bischof M, Mauskopf JA, Setyawan J. Zimovetz EA, et al. Among authors: bischof m. CNS Drugs. 2016 Oct;30(10):985-96. doi: 10.1007/s40263-016-0354-3. CNS Drugs. 2016. PMID: 27530525 Free PMC article.

10

Body of Evidence for Onasemnogene Abeparvovec in Spinal Muscular Atrophy Supports Long-Term Duration of Effect Without Relapse.

Dean R, Dabbous O, Weidlich D, Bischof M. Dean R, et al. Among authors: bischof m. Value Health. 2022 Nov;25(11):1922-1923. doi: 10.1016/j.jval.2021.10.019. Epub 2022 Feb 16. Value Health. 2022. PMID: 35181208 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

266 results

Search Page

Filters